clinical trial · NCT03598790
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL·phase3·completed·n = 1,353
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisBimekizumab
brief summary
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
started
Sep 5, 2018
primary completion
Nov 14, 2023
completion
Nov 14, 2023
last updated
Apr 15, 2026
detailed description
The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.
official title
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol